Helix BioPharma (GM) Stock Price - HBPCF

0.89
0.00 (0.0%)
0.89
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Canna Trader Pro
Monthly Subscription
for only
$59.99
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Helix BioPharma Company (GM) HBPCF OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.89 0.00 0.00 0.00 0.89 20:00:00
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.89 USD

Helix BioPharma (GM) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 118.31M 132.93M 33.42M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
5.00k $ - 0.00% - -

more financials information »

Helix BioPharma (GM) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HBPCF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.991.0080.890.9951003800-0.10-10.1%
3 Months1.101.14810.891.04596-0.21-19.09%
6 Months0.870291.14810.85960.99190431,0130.019712.26%
1 Year0.231.14810.210020.54530372,9520.66286.96%
3 Years0.72141.14810.210020.51899163,2560.168623.37%
5 Years1.4811.6540.210020.79195733,441-0.591-39.91%

Helix BioPharma (GM) Description

Helix BioPharma is a biopharmaceutical company specializing in the field of cancer therapy. The Company is developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's clinical product development initiatives include Topical Interferon Alpha-2b, for the treatment of conditions caused by the human papilloma virus. Helix is also developing its novel L-DOS47 new drug product candidate for the treatment of lung adenocarcinoma.


Your Recent History
USOTC
HBPCF
Helix BioP..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.